Patent · US Active

Method of determining the sensitivity of cancer cells to EGFR inhibitors including cetuximab, panitumumab and erlotinib

US8137919B2 · kind B2 · utility

1Cited by
0References
11Claims
0Family size

Assignee

Inventors

Key dates

Filing dateApr 8, 2009
Grant dateMar 20, 2012
Priority date—
Expiry dateApr 14, 2030

Classification

  • Technology area (CPC G)Physics
  • CPC primaryG01N2800/52
  • WIPO fieldMeasurement
  • WIPO sectorInstruments

Abstract

A method of determining if a cancer patient is amenable to treatment with EGFR inhibitors including but not limited to cetuximab, panitumumab or erlotinib by the following steps:

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.